Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TYK2 inhibition reduces type 3 immunity and modifies disease progression in murine spondyloarthritis.

The Journal of clinical investigation - 1 Apr 2020

Gracey Eric, Hromadová Dominika, Lim Melissa, Qaiyum Zoya, Zeng Michael, Yao Yuchen, Srinath Archita, Baglaenko Yuriy, Yeremenko Natalia, Westlin William, Masse Craig, Müller Mathias, Strobl Birgit, Miao Wenyan, Inman Robert D

Abstract excerpt

Spondyloarthritis (SpA) represents a family of inflammatory diseases of the spine and peripheral joints. Ankylosing spondylitis (AS) is the prototypic form of SpA in which progressive disease can lead to fusion of the spine. Therapeutically, knowledge of type 3 immunity has translated into the development of IL-23- and IL-17A-blocking antibodies for the treatment of SpA. Despite being able to provide symptomatic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Interleukins
Share to Mice

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Polymorphism, Single Nucleotide

Share to Protein Kinase Inhibitors

Share to Signal Transduction

Share to Spondylarthritis

Share to TYK2 Kinase

Source

Open in PubMed Open full text

Identifiers

PMID: 32149730
DOI: 10.1172/JCI126567
PMCID: PMC7108927

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TYK2 inhibition reduces type 3 immunity and modifies disease progression in murine spondyloarthritis.PMID 32149730Read ↗

The TYK2-P1104A Autoimmune Protective Variant Limits Coordinate Signals Required to Generate Specialized T Cell SubsetsSemantic proximity Read ↗

Therapeutic potential of tyrosine kinase 2 in autoimmunity.Semantic proximity Read ↗

A Restricted Role for TYK2 Catalytic Activity in Human Cytokine Responses Revealed by Novel TYK2-Selective InhibitorsSemantic proximity Read ↗

Tyk2 Targeting in Immune-Mediated Inflammatory DiseasesSemantic proximity Read ↗

Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunitySemantic proximity Read ↗

A review of JAK–STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibitionSemantic proximity Read ↗

Illuminating the impact of γδ T cells in man and mice in spondylarthritides.Semantic proximity Read ↗

Pharmacological inhibition of tyrosine protein-kinase 2 reduces islet inflammation and delays type 1 diabetes onset in miceSemantic proximity Read ↗

A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity.Semantic proximity Read ↗

TYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traits.Semantic proximity Read ↗

IL-23 Inhibition in Ankylosing Spondylitis: Where Did It Go Wrong?Semantic proximity Read ↗

Role of Tyk-2 in Th9 and Th17 cells in allergic asthma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.